ArticleBlood advances2023

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.

Maissa Mhibik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.